These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A look at HIV immune research. Interview by Alan Huff. Landay A Res Initiat Treat Action; 2000 Sep; 6(3):30-3. PubMed ID: 11708165 [No Abstract] [Full Text] [Related]
4. Decreased apoptosis despite severe CD4 depletion in the thymus of a human immunodeficiency virus-1 infected child. Brunner J; Boehler T; Ehemann V; Kassam S; Otto H; Sergi C Klin Padiatr; 2011 Jul; 223(4):246-8. PubMed ID: 21271506 [TBL] [Abstract][Full Text] [Related]
5. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239 [TBL] [Abstract][Full Text] [Related]
6. The dynamics of CD4+ T-cell depletion in HIV disease. McCune JM Nature; 2001 Apr; 410(6831):974-9. PubMed ID: 11309627 [TBL] [Abstract][Full Text] [Related]
7. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. Marchetti G; Meroni L; Molteni C; Bandera A; Franzetti F; Galli M; Moroni M; Clerici M; Gori A AIDS; 2004 Jan; 18(2):211-6. PubMed ID: 15075538 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes. Sousa AE; Chaves AF; Loureiro A; Victorino RM J Infect Dis; 2001 Sep; 184(5):552-9. PubMed ID: 11494161 [TBL] [Abstract][Full Text] [Related]
10. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-15 is a potent survival factor in the prevention of spontaneous but not CD95-induced apoptosis in CD4 and CD8 T lymphocytes of HIV-infected individuals. Correlation with its ability to increase BCL-2 expression. Naora H; Gougeon ML Cell Death Differ; 1999 Oct; 6(10):1002-11. PubMed ID: 10556978 [TBL] [Abstract][Full Text] [Related]
12. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. De Paoli P; Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Talamini R; Comar M; Giacca M; Tirelli U J Clin Invest; 1997 Dec; 100(11):2737-43. PubMed ID: 9389737 [TBL] [Abstract][Full Text] [Related]
13. Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects. Caggiari L; Zanussi S; Crepaldi C; Bortolin MT; Caffau C; D'Andrea M; De Paoli P Cytometry; 2001 Aug; 46(4):233-7. PubMed ID: 11514956 [TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439 [TBL] [Abstract][Full Text] [Related]
16. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Li T; Wu N; Dai Y; Qiu Z; Han Y; Xie J; Zhu T; Li Y Clin Infect Dis; 2011 Nov; 53(9):944-51. PubMed ID: 21960716 [TBL] [Abstract][Full Text] [Related]
17. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system. Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348 [TBL] [Abstract][Full Text] [Related]
18. The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player. Khoury G; Rajasuriar R; Cameron PU; Lewin SR Clin Immunol; 2011 Dec; 141(3):253-67. PubMed ID: 21996455 [TBL] [Abstract][Full Text] [Related]
19. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700 [TBL] [Abstract][Full Text] [Related]
20. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]